Columvi
Novartis presents positive results from two phase 3 trials for relapsing MS
Remibrutinib reduced relapse rates and improved disease progression rates
Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer
The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care
AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo
The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA
Pfizer’s Litfulo significantly improved repigmentation in nonsegmental vitiligo
NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment
Biogen announces phase 2 data for cutaneous lupus erythematosus
The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity
Invited, but not equipped: patient involvement needs more than an open door
Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.
Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS
If approved, this treatment would offer a new option for the nearly one million Americans living with MS
Long-term clinical trial engagement is a behavioural challenge – not just an informational one
Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.
Patients are telling the truth — just not to you
Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.
Roche and Dualitas Therapeutics announce research collaboration worth up to $1bn
The two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases
When what matters to patients is hard to measure
Patient-relevant outcomes sit at the heart of the EU HTA reforms, but ensuring they reflect lived experience requires you to look beyond what traditional clinical endpoints measure.
Roche’s Enspryng gets FDA Priority Review for autoimmune disease with no approved treatments
MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain